Research and Markets: Stakeholder Insight: Rheumatoid Arthritis - Rising ... - Kansas City Star

Research and Markets: Stakeholder Insight: Rheumatoid Arthritis - Rising ... Kansas City Star In 2010, traditional DMARDs are the foundation of drug therapy in rheumatoid arthritis and will remain at the core of treatment going forward. Methotrexate ... and more »

Syk Inhibitor Shows Promise as Oral Agent in Rheumatoid Arthritis - Medscape

MD News (press release)

Syk Inhibitor Shows Promise as Oral Agent in Rheumatoid Arthritis Medscape ... rheumatoid arthritis (RA), a Syk inhibitor, R788, reduced disease activity compared with placebo despite receiving long-term methotrexate therapy, ... Novel Rheumatoid Arthritis Drug Shows Early PromiseBusinessWeek Rigel Arthritis Drug Passes TrialXconomy Syk Inhibitor May Help RAMedPage Today FierceBiotech -StreetInsider.com (subscription) -MarketWatch (press release) all 37 news articles »

Better Outcomes With Combo Therapy in Early RA - MedPage Today

Better Outcomes With Combo Therapy in Early RA MedPage Today Patients with rheumatoid arthritis who received initial combination therapy with adalimumab (Humira) plus methotrexate for two years had better long-term ... RA patients who undergo combination therapy more likely to control the diseaseTREND all 2 news articles »

Centocor seeks expansion of Simponi use - Philadelphia Business Journal

Centocor seeks expansion of Simponi use Philadelphia Business Journal It was also approved at that time as a combination treatment with the drug Methotrexate for moderate-to-severe rheumatoid arthritis. Rheumatoid arthritis is ... Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand ...PR Newswire (press release) all 17 news articles »